Eli Lilly & Co. (LLY): What Does the Patent Cliff Mean for This Drugmaker?
For Eli Lilly & Co. (NYSE:LLY), history is repeating itself once again.
Posts Tagged ‘NYSE:LLY’
AstraZeneca plc (ADR) (AZN), Eli Lilly & Co. (LLY): The Diabetes Pipeline With a Clog
Big pharma placed its bets on a new class of diabetes drugs called SGLT2. Last year, buzz surrounded late-stage projects from Johnson and Johnson (NYSE:JNJ), Eli Lilly & Co.
Alexion Pharmaceuticals, Inc. (ALXN), Eli Lilly & Co. (LLY): Five Drugmakers With a Lot on the Line
You may or may not have heard, but it's earnings season again.
Three Key Takeaways From Johnson & Johnson (JNJ)’s Q2
Johnson & Johnson (NYSE:JNJ) reported its second quarter on Tuesday, and turned in some positive numbers. Revenue grew 8.5%, year-over-year, up to $17.9 billion.
The Future of Sanofi SA (ADR) (SNY)’s Insulin Empire
Sanofi SA (ADR) (NYSE:SNY) appeared at the American Diabetes Association meeting last month, touting data for the new insulin U300 and a combo therapy involving its approved drugs...
Eli Lilly & Co. (LLY), Teva Pharmaceutical Industries Ltd (ADR) (TEVA): The 3 Most Commonly Diagnosed Mental Disorders
The medical community certainly spends a lot of time and money researching treatments for cardiovascular disease and cancer.
Could This Safe Play Help Eli Lilly & Co. (LLY)?
At the American Diabetes Association meeting last month, Eli Lilly & Co. (NYSE:LLY) presented promising data for the GLP-1 agonist dulaglutide.
Drug Deal Can Only Help VIVUS, Inc. (VVUS) So Much
VIVUS, Inc. (NASDAQ:VVUS) has found an Italian to help it out.
Could This Safe Play Help Eli Lilly & Co. (LLY)?
At the American Diabetes Association meeting last month, Eli Lilly & Co. (NYSE:LLY) presented promising data for the GLP-1 agonist dulaglutide.
Allergan, Inc. (AGN): A New Migraine Therapy That Can Address a Major Demand
One-fourth of all migraine patients suffer nasty side effects from the market's dominant migraine-fighting treatments.
Spectrum Pharmaceuticals, Inc. (SPPI): Is This Biotech for Sale?
For the last five years, Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) CEO Rajesh Shrotriya has always insisted that Spectrum Pharmaceuticals, Inc.
GlaxoSmithKline plc (ADR) (GSK): Why You Should Buy This European Healthcare Company
Investors who buy stock in the major pharmaceutical companies likely do so because of several factors, including steady growth, modest valuations, and high dividend yields.
AstraZeneca plc (ADR) (AZN), PDL BioPharma Inc. (PDLI): Tempting Healthcare Dividend Stocks to Avoid
When screening for health-care dividend stocks, it's tempting to look for the ones with the highest yield.
Is Zoetis Inc (ZTS) Worth the Premium?
After all of the hype and hoopla over Pfizer Inc.
Three Things That Will Move AbbVie Inc (ABBV) Stock
AbbVie Inc (NYSE:ABBV) has risen more than 20% since it hit the market earlier this year. In fact, it has managed to beat the S&P 500 by nearly 10%.
Pfizer Inc. (PFE), Eli Lilly & Co. (LLY), Baxter International Inc. (BAX): Three Solid Long-Term Pharma Picks
Moreover, there is a rising demand for good healthcare in developing countries in the Asia-Pacific region.
Eli Lilly & Co. (LLY), Bristol Myers Squibb Co. (BMY): Can’t Anyone Tackle Alzheimer’s?
After a series of failures, one is forced to wonder whether the medical fraternity, including the research and development wing of Eli Lilly & Co.
Pfizer Inc. (PFE), VIVUS, Inc. (VVUS): Cheap Viagra That Americans Can’t Buy
Cheap generic versions of Pfizer Inc. (NYSE:PFE)'s Viagra are coming to Europe, according the generic-drug maker Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA).
Is This What the Doctor Ordered for Eli Lilly & Co. (LLY)?
After the failure of its pipeline products for Alzheimer’s and rheumatoid arthritis, the drug giant Eli Lilly & Co. (NYSE:LLY) finally has some good news to report.
Buy Johnson & Johnson (JNJ)?
Stocks that stand the test of time are often ones that have a diversified product portfolio of world class brands.
Raynor: What Makes Merck & Co., Inc. (MRK) an Exceptional Company
A director at Deloitte Services LP and co-author of The Three Rules: How Exceptional Companies Think, Michael Raynor joins The Fool to share his findings about what makes a company...
Why Loss of Viagra Patent Will Not Harm Pfizer Inc. (PFE)
Viagra changed the way below-the-belt jokes were told, and certainly, it empowered a lot of men in ways they couldn't have imagined. Without a doubt, Pfizer Inc.
AstraZeneca plc (ADR) (AZN), GlaxoSmithKline plc (ADR) (GSK): Will These Pharma Stocks Maintain Their Yields?
High dividend pharmaceutical stocks have been extremely popular in recent years.
Sanofi SA (ADR) (SNY), Bristol Myers Squibb Co. (BMY): The Diabetes Drug War
Technological advances have allowed for people to have more longevity. Drug companies research and develop medicines to prevent, control and cure diseases.
Eli Lilly & Co. (LLY): Is a Type 1 Diabetes Cure Right Around the Corner?
For lack of a better phrase, those who have type 1 diabetes -- a form of diabetes whereby the person's own autoimmune system attacks or attempts to destroy cells in the pancreas...
Why MannKind Corporation (MNKD) Is Poised to Pull Back
Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, biopharmaceutical company MannKind Corporation...
Dynavax Technologies Corporation (DVAX), Elan Corporation, plc (ADR) (ELN): This Week in Biotech
With the SPDR S&P Biotech Index up 29% over the trailing-12-month period, it's evident that investment dollars are willingly flowing into the biotech sector.
Eli Lilly & Co. (LLY), Merck & Co., Inc. (MRK): Another Alzheimer’s Disease Failure
The latest drug to bite the dust is LY2886721, a beta secretase, or BACE, inhibitor.
Amgen, Inc. (AMGN), Bristol Myers Squibb Co. (BMY): Ovarian Cancer Drug Half Way There
The biotech giant announced today that its cancer drug trebananib combined with chemotherapy paclitaxel extended median progression-free survival in recurrent ovarian cancer patients...
Johnson & Johnson (JNJ): Is This Healthcare Company a Strong Investment?
The slowdown in stock market has also adversely affected leading healthcare companies’ stocks.
Is Pfizer Inc. (PFE) a Buy?
The biggest pharmaceutical companies in the United States are in an enviable position. They sell products that are literally a matter of life and death.
Google Inc (GOOG), Lennar Corporation (LEN): Billionaire Stanley Druckenmiller’s Big 5
Billionaire Stanley Druckenmiller founded his Duquesne Capital hedge fund in 1981. It now has some $10 billion in assets under management.
GlaxoSmithKline plc (ADR) (GSK), Merck & Co., Inc. (MRK): Why You Should Care About This Diabetes Drug Saga
GlaxoSmithKline plc (ADR) (NYSE:GSK)'s diabetes drug Avandia causes heart issues. Or maybe it doesn't.
Should You Buy AstraZeneca plc (ADR) (AZN)?
Is AstraZeneca plc (ADR) (NYSE:AZN) a healthy stock for your portfolio? Investors who are in the know are getting more bullish.
Google Inc (GOOG), Eli Lilly & Co. (LLY) and More: Billionaire Jim Simons’ Buy Ups
Billionaire Jim Simons founded Renaissance Technologies ("RenTech"), his private investment firm, in 1982.
Pfizer Inc. (PFE): Big Things Are Happening at This Pharmaceutical Company
Pharmaceutical company Pfizer Inc. (NYSE:PFE) has been doing some interesting things lately.
Sarissa’s Stake in Vivus, Inc. (VVUS) Points to Renewed Interest in the Company
Noted hedge fund Sarissa Capital Management recently disclosed a stake of nearly 2% in promising biotechnology firm VIVUS, Inc. (NASDAQ:VVUS) .
Pfizer Inc. (PFE)’s Big Chance
When we think of big pharma companies, the company we think about constantly is Pfizer Inc.
Eli Lilly & Co. (LLY), Medtronic, Inc. (MDT): Profiting from Diabetes Expenses
In the past I have found success investing in companies that provide exposure to growing themes.
Synta Pharmaceuticals Corp. (SNTA): A Promising Biotech Stock for 2013
Biotechnology stocks offer investors some of the highest potential for returns of any industry.
Merck & Co., Inc. (MRK), Celgene Corporation (CELG): 3 FDA Stories You Missed Last Week
Editor's Note: The initial article refers to Abraxane's prostate cancer trials. That is incorrect, Abraxane has priority review for pancreatic cancer.
Merck & Co., Inc. (MRK), GlaxoSmithKline plc (ADR) (GSK): Three FDA Stories You Missed Last Week
The Food and Drug Administration stays busy with approvals, recommendations, and reviews.
AbbVie Inc (ABBV): Hedge Funds and Insiders Are Bullish, What Should You Do?
According to most market participants, hedge funds are assumed to be underperforming, old financial vehicles of yesteryear.
Pfizer Inc. (PFE), Zoetis Inc (ZTS): 4 Investment Opportunities in Animal Health
Pfizer Inc. (NYSE:PFE) recently announced plans to sell its remaining 80% stake in animal-health company Zoetis Inc (NYSE:ZTS) after about four months on the public market.
Should You Trade Pfizer Inc. (PFE) Stock for Shares in Zoetis Inc (ZTS)?
Owners of Pfizer Inc. (NYSE:PFE) stock have an animal of a decision to make.
Eli Lilly & Co. (LLY): Hedge Funds and Insiders Are Bearish, What Should You Do?
Eli Lilly & Co. (NYSE:LLY) was in 35 hedge funds' portfolio at the end of the first quarter of 2013.
Will Pipeline Disasters Devour Eli Lilly & Co. (LLY) Stock?
Eli Lilly & Co. (NYSE:LLY) investors just can't catch a break lately.
Pfizer Inc. (PFE), Merck & Co., Inc. (MRK), Teva Pharmaceutical Industries Ltd (ADR) (TEVA): Four Big Drug Companies With Big Juicy Yields
Drug companies have been revenue generating machines for long.
AstraZeneca plc (ADR) (AZN), GlaxoSmithKline plc (ADR) (GSK), Merck & Co., Inc. (MRK), Eli Lilly & Co. (LLY), AbbVie Inc (ABBV): The 5 Highest-Paying Dividend Stocks in Big Pharma
Any investor looking for the highest-paying dividend stocks would do well to start in Big Pharma, where many of the top picks offer yields in excess of 3% or 4%.
